London/Utrecht, 28 November 2012 – AI Garden B.V. (the Offeror), a company ultimately indirectly controlled by funds advised and managed by Advent International Corporation (Advent) and Mediq N.V. (Mediq) jointly announce that the Offeror has obtained regulatory clearance from the European Commission and the relevant antitrust authority in the United States in connection with the Offeror’s recommended all-cash public offer for all the issued and outstanding ordinary shares (the Shares) in the capital of Mediq (the Offer). As a result, the Offer Condition in relation to competition clearance has been satisfied.
The Offeror is making the Offer on the terms and subject to the conditions and restrictions contained in the Offer Memorandum, dated 8 November 2012. In addition, Mediq has made available the Position Statement, containing the information required by
Article 18, paragraph 2 and Annex G of the Decree in connection with the Offer.
This announcement contains selected, condensed information regarding the Offer and does not replace the Offer Memorandum and/ or the Position Statement. The information in this announcement is not complete and additional information is contained in the Offer Memorandum and the Position Statement.
Shareholders are advised to review the Offer Memorandum and the Position Statement in detail and to seek independent advice where appropriate in order to reach a reasoned judgment in respect of the Offer and the content of the Offer Memorandum and the Position Statement.
Copies of the Offer Memorandum are available free of charge at the offices of the Offeror, Mediq and the Paying and Exchange Agent Rabobank International and can be obtained by contacting the Offeror, Mediq or the Paying and Exchange Agent.
Digital copies of the Offer Memorandum are available on the websites of Mediq (www.mediq.com) and Advent (www.adventinternational.com). The Mediq and Advent
websites do not constitute a part of, and are not incorporated by reference into, the Offer Memorandum. Digital copies of the Position Statement are available on the website of Mediq (www.mediq.com).
For more information
For media enquiries:
Advent Media Relations
Fergus Wheeler / Josephine Corbett
Tel: +44 (0) 207 269 7259 / 7250
Catrien van Buttingha Wichers
T +31 (0)30 282 16 09
M +31 (0)6 5339 3665
For media enquiries:
T +31 (0)30 282 1061
M +31 (0)6 2219 7204
About Advent International
Founded in 1984, Advent International is one of the world’s leading global buyout firms, with offices in 16 countries on four continents. A driving force in international private equity for 28 years, Advent has built an unparalleled global platform of over 170 investment professionals across Western and Central Europe, North America, Latin America and Asia. The firm focuses on international buyouts, strategic repositioning opportunities and growth buyouts in five core sectors, working actively with management teams to drive revenue growth and earnings improvements in portfolio companies. Since inception, Advent has raised €28 billion in private equity capital and, through its buyout
programmes, has completed over 279 transactions in 35 countries. For more information, visit www.adventinternational.com.
Mediq is an international company delivering pharmaceuticals, medical devices and related care services. The patient is at the centre of everything we do. Mediq delivers via three channels: direct to people’s homes (Direct), via hospitals, nursing homes and other healthcare institutions (Institutional) and via Mediq Pharmacies. Mediq operates in 15 countries. Its head office is located in Utrecht, the Netherlands. The company was founded in 1899 and has around 8,300 employees. Mediq is listed on Euronext Amsterdam. Mediq reported € 2.7 billion net sales in 2011. For more information see www.mediq.com.